Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 5NIH 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 10Neurofibromatosis 1 9Breast Neoplasms 5Neurofibroma, Plexiform 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Neurofibrosarcoma 3Thyroid Neoplasms 2Neoplasms 2Melanoma 2Gallbladder Neoplasms 2Uveal Melanoma 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Meningioma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × AZD 6244 × Clear all
NCT01256359 2024-08-15

DOC-MEK

University of Oxford

Phase 2 Completed
83 enrolled 60 charts
Dermatologic

Melanoma

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

Columbia University

Phase 1 Completed
42 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡